Marilyn Matz, Chief Executive Officer and Co-Founder, Paradigm4 “Genomics’ role in the life science vision “is only as credible as its implementation,”
Marilyn Matz, Chief Executive Officer and Co-Founder, Paradigm4 “Genomics’ role in the life science vision “is only as credible as its implementation,”
BOSTON — Paradigm4 has today unveiled REVEAL™: Proteomics, the newest use case specific app powered by the Paradigm4 FLASH™ high-performance bioinformatics platform. REVEAL: Proteomics unlocks the power of advanced mass spec proteomics by simplifying cross sample and cross study searching for protein isoforms as potential biomarkers for drug response or
Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.
Zach Pitluk, Ph.D.